Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07170046
NCT07170046Not yet recruitingNot Applicable

Predictive Value of CEA and ctDNA for Postoperative Recurrence in Patients With High CEA Sensitivity Lung Cancer

Guangdong Provincial People's Hospital0 sites100 target enrollmentStarted: September 15, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
100
Primary Endpoint
Postoperative tumor recurrence or progression
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.

Detailed Description

This study will collect two groups of cohorts: prospective and retrospective.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Eligibility Criteria

Ages
15 Years to 100 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Preoperative CEA > 5mg/l
  • •MRD testing was conducted before the operation
  • •The primary lesion was resected through surgery
  • •There should be at least two CEA and MRD follow-up tests within 2 years after the operation
  • •Postoperative pathology confirmed it as a malignant lung tumor

Exclusion Criteria

  • •Those without available imaging records
  • •Patients with a history of malignant tumors within the past five years
  • •Patients with secondary lung cancer

Outcomes

Primary Outcomes

Postoperative tumor recurrence or progression

Time Frame: 2 years

If the tumor recurs or progresses within 2 years, it will be marked as 1. If not, it will be marked as 0.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Recruiting
Not Applicable
A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal MetastasesColorectal Cancer
NCT06903325Fudan University50
Not yet recruiting
Phase 1
Trial of ctDNA of Guidance to Determine PostOperative Radiation TherapyLung Cancer
NCT06979661Rutgers, The State University of New Jersey25
Recruiting
Not Applicable
Predictive Value of Preoperative Evaluation in Cases of Recurrent EndometriosisEndometriosis
NCT06132009Bagcilar Training and Research Hospital64
Recruiting
Not Applicable
Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung CancerNSCLC
NCT06081777Peking University Cancer Hospital & Institute65
Active, not recruiting
Not Applicable
Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer RecurrenceColorectal Cancer
NCT06143644Sun Yat-sen University220